针对表面活性剂功能障碍的遗传疾病的个性化疗法
Maureen Peers de Nieuwburgh1, Jennifer A Wambach2, Matthias Griese3
1Division of Neonatology, Department of Pediatrics, St-Luc University Hospital, Catholic University of Louvain, Brussels, Belgium.
Seminars in fetal & neonatal medicine
|November 30, 2023
概括
遗传表面活性剂功能障碍会导致婴儿严重呼吸衰竭. 早期诊断和遗传评估是个性化治疗的关键,如基因疗法,改善受影响儿童的结果.
科学领域:
- 肺部医学 肺部医学
- 遗传学 是一个遗传学.
- 儿科呼吸系统医学 儿科呼吸系统医学
背景情况:
- 影响肺表面活性剂的遗传性疾病是婴儿呼吸衰竭的罕见但严重的原因.
- 这些情况可以导致慢性,渐进的或不耐药的呼吸系统问题,无论是期满还是早产的新生儿.
研究的目的:
- 审查表面活性剂功能障碍的遗传机制.
- 突出涉及的关键基因 (SFTPB,SFTPC,ABCA3,NKX2.1) 和它们相关的临床表现.
- 讨论诊断和治疗策略,包括新出现的选择.
主要方法:
- 关于表面活性剂功能障碍的遗传疾病的文献综述.
- 临床表现和遗传基础的分析.
- 探索当前和未来的治疗方式.
主要成果:
- SFTPB,SFTPC,ABCA3和NKX2.1中的致病变体会导致一系列的呼吸系统疾病.
- 呈现范围从新生儿缺血性呼吸衰竭到儿童间歇性肺病和成人肺纤维化.
- 早期识别,表型评估和变体分析对于有效管理至关重要.
结论:
- 遗传表面活性剂功能障碍需要多方面的方法,包括遗传见解和临床评估.
- 个性化药理疗法和基因疗法是未来有希望的方向.
- 进一步的研究对于开发适合受影响个体的定制疗法至关重要.
相关概念视频
Cystic Fibrosis: Management
172
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
172
Breathing
59.3K
The process of breathing, inhaling and exhaling, involves the coordinated movement of the chest wall, the lungs, and the muscles that move them. Two muscle groups with important roles in breathing are the diaphragm, located directly below the lungs, and the intercostal muscles, which lie between the ribs. When the diaphragm contracts, it moves downward, increasing the volume of the thoracic cavity and creating more room for the lungs to expand. When the intercostal muscles contract, the ribs...
59.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Acute Respiratory Failure-V
142
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
142
Cystic Fibrosis: Pathogenesis
252
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
252


